Literature DB >> 10200343

Reduced expression of the CXCR4 receptor mRNA in hepatocellular carcinoma and lack of inducibility of its ligand alpha-chemokine hIRH/SDF1alpha/PBSF in vitro.

N A Begum1, K Shibuta, M Mori, G F Barnard.   

Abstract

Differential cDNA displays between hepatocellular carcinoma and adjacent non-malignant tissues have previously detected a PCR product, hIRH (human intercrine reduced in hepatomas), equivalent to SDF1alpha/PBSF whose mRNA was lost from human hepatocellular carcinoma and other malignant and pre-malignant samples and malignant cell lines. There are no reports to date of the mRNA status of the receptor for hIRH/SDF1alpha/PBSF, CXCR4 in malignant tissues. We report here that there is a reduction in the mRNA expression of CXCR4 in hepatocellular carcinoma as estimated by Northern blot and RT-PCR and compared to the adjacent non-malignant tissue. The average (mean SD) tumor/normal ratio for CXCR4 mRNA expression, determined by RT-PCR, was 0.65 0.36 in 10 pairs of hepatocellular carcinomas. There was no consistent loss of CXCR4 mRNA expression in a range of malignant cell lines. The 3'-non-coding region of hIRH, had typical early response gene element sequences. Despite the presence of these 3'-elements there was no induction of hIRH gene expression in human lung carcinoma A549 cells by tumor necrosis factor alpha, interleukin-2, lipopolysaccharide or phorbol myristic acetate, nor in human melanoma cell line SB-2 by uv irradiation, under conditions which induced the homologue CXC intercrine IL-8 expression. Furthermore, there was no induction of hIRH gene expression, but rather a suppression, upon serum or cytokine addition to serum-deprived fibroblast cell lines, to an in vitro mouse bone marrow preparation, and to monocytic cell line THP-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200343     DOI: 10.3892/ijo.14.5.927

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential.

Authors:  Tong-Chun Xue; Rong-Xin Chen; Dan Han; Jie Chen; Qiong Xue; Dong-Mei Gao; Rui-Xia Sun; Zhao-You Tang; Sheng-Long Ye
Journal:  Exp Ther Med       Date:  2011-09-29       Impact factor: 2.447

Review 2.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

3.  Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis.

Authors:  Linhui Wang; Liang Wang; Bo Yang; Qing Yang; Shouyi Qiao; Yingming Wang; Yinghao Sun
Journal:  Clin Exp Metastasis       Date:  2009-10-27       Impact factor: 5.150

4.  Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines.

Authors:  Seong-Woo Kim; Ha-Yon Kim; Ik-Chan Song; Seon-Ah Jin; Hyo-Jin Lee; Hwan-Jung Yun; Samyong Kim; Deog-Yeon Jo
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

5.  CXCR4/CXCL12 expression and signalling in kidney cancer.

Authors:  A J Schrader; O Lechner; M Templin; K E J Dittmar; S Machtens; M Mengel; M Probst-Kepper; A Franzke; T Wollensak; P Gatzlaff; J Atzpodien; J Buer; J Lauber
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

6.  The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors.

Authors:  Chao Zhang; Fang-Yuan Chang; Wen-Ya Zhou; Ji-Long Yang
Journal:  Chin J Cancer       Date:  2017-10-11

7.  Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation.

Authors:  Kenji Shibuta; Masaki Mori; Katsuhiro Shimoda; Hiroshi Inoue; Prasenjit Mitra; Graham F Barnard
Journal:  Jpn J Cancer Res       Date:  2002-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.